Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model

Filamentous tau inclusions are hallmarks of Alzheimer's disease (AD) and related tauopathies, but earlier pathologies may herald disease onset. To investigate this, we studied wild-type and P301S mutant human tau transgenic (Tg) mice. Filamentous tau lesions developed in P301S Tg mice at 6 months of age, and progressively accumulated in association with striking neuron loss as well as hippocampal and entorhinal cortical atrophy by 9-12 months of age. Remarkably, hippocampal synapse loss and impaired synaptic function were detected in 3 month old P301S Tg mice before fibrillary tau tangles emerged. Prominent microglial activation also preceded tangle formation. Importantly, immunosuppression of young P301S Tg mice with FK506 attenuated tau pathology and increased lifespan, thereby linking neuroinflammation to early progression of tauopathies. Thus, hippocampal synaptic pathology and microgliosis may be the earliest manifestations of neurodegenerative tauopathies, and abrogation of tau-induced microglial activation could retard progression of these disorders.

[1]  P. Davies,et al.  A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Bin Zhang,et al.  Axonal transport defects: a common theme in neurodegenerative diseases , 2005, Acta Neuropathologica.

[3]  F. Muramori,et al.  A quantitative study of neurofibrillary tangles, senile plaques and astrocytes in the hippocampal subdivisions and entorhinal cortex in Alzheimer's disease, normal controls and non‐Alzheimer neuropsychiatric diseases , 1998, Psychiatry and clinical neurosciences.

[4]  Bin Zhang,et al.  Retarded Axonal Transport of R406W Mutant Tau in Transgenic Mice with a Neurodegenerative Tauopathy , 2004, The Journal of Neuroscience.

[5]  J. Trojanowski,et al.  Regions with abundant neurofibrillary pathology in human brain exhibit a selective reduction in levels of binding-competent tau and accumulation of abnormal tau-isoforms (A68 proteins). , 1992, Laboratory investigation; a journal of technical methods and pathology.

[6]  Dennis W. Dickson,et al.  Tau accumulation in astrocytes in progressive supranuclear palsy is a degenerative rather than a reactive process , 2002, Acta Neuropathologica.

[7]  J. Trojanowski,et al.  A panel of epitope‐specific antibodies detects protein domains distributed throughout human α‐synuclein in lewy bodies of Parkinson's disease , 2000, Journal of neuroscience research.

[8]  J. Trojanowski,et al.  The phosphorylation state of tau in the developing rat brain is regulated by phosphoprotein phosphatases. , 1994, The Journal of biological chemistry.

[9]  E. Bigio,et al.  Cortical Synapse Loss in Progressive Supranuclear Palsy , 2001, Journal of neuropathology and experimental neurology.

[10]  J. Kril,et al.  Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation , 2002, Acta Neuropathologica.

[11]  M. Staufenbiel,et al.  Neprilysin-sensitive Synapse-associated Amyloid-β Peptide Oligomers Impair Neuronal Plasticity and Cognitive Function* , 2006, Journal of Biological Chemistry.

[12]  C. Duyckaerts,et al.  Glial fibrillary acidic protein and βA4 protein deposits in temporal lobe of aging brain and senile dementia of the Alzheimer type: Relation with the cognitive state and with quantitative studies of senile plaques and neurofibrillary tangles , 1990, Journal of neuroscience research.

[13]  M. Matsui,et al.  A Japanese patient with frontotemporal dementia and parkinsonism by a tau P301S mutation , 2000, Neurology.

[14]  S. Reske,et al.  FTDP‐17: An early‐onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation , 1999, Annals of neurology.

[15]  Yuji Nagai,et al.  Novel peripheral benzodiazepine receptor ligand [11C]DAA1106 for PET: An imaging tool for glial cells in the brain , 2004, Synapse.

[16]  J. Trojanowski,et al.  Epitopes that span the tau molecule are shared with paired helical filaments , 1988, Neuron.

[17]  John X. Morris,et al.  Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. , 1998, Science.

[18]  E. Rodríguez,et al.  Standardization of various applications of methacrylate embedding and silver methenamine for light and electron microscopy immunocytochemistry , 2004, Histochemistry.

[19]  J. Gomori,et al.  Frontotemporal dementia and parkinsonism with the P301S tau gene mutation in a Jewish family , 2003, Journal of Neurology.

[20]  John Q Trojanowski,et al.  Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs , 2004, Nature Medicine.

[21]  M. Goedert,et al.  Molecular Pathogenesis of Genetic and Inherited Diseases Induction of Inflammatory Mediators and Microglial Activation in Mice Transgenic for Mutant Human P301S Tau Protein , 2004 .

[22]  Bin Zhang,et al.  Age-Dependent Emergence and Progression of a Tauopathy in Transgenic Mice Overexpressing the Shortest Human Tau Isoform , 1999, Neuron.

[23]  M. Guazzelli,et al.  Tau gene mutation G389R causes a tauopathy with abundant pick body-like inclusions and axonal deposits. , 1999, Journal of neuropathology and experimental neurology.

[24]  E. Masliah,et al.  Altered expression of synaptic proteins occurs early during progression of Alzheimer’s disease , 2001, Neurology.

[25]  E. Bigio,et al.  Contribution of asymmetric synapse loss to lateralizing clinical deficits in frontotemporal dementias. , 2001, Archives of neurology.

[26]  C. Duijn,et al.  High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. , 1999, American journal of human genetics.

[27]  K. Arai,et al.  Expression of invariant chain and pro-cathepsin L in Alzheimer's brain , 2000, Neuroscience Letters.

[28]  S. Lovestone,et al.  Mutations in tau reduce its microtubule binding properties in intact cells and affect its phosphorylation , 1999, FEBS letters.

[29]  J. Trojanowski,et al.  Neurodegenerative tauopathies. , 2001, Annual review of neuroscience.

[30]  P. Lantos,et al.  Neuronal loss and neurofibrillary degeneration in the hippocampal cortex in late‐onset sporadic Alzheimer's disease , 2000, Psychiatry and clinical neurosciences.

[31]  G. Schellenberg,et al.  Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[32]  D. Mann,et al.  A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease , 1987, Journal of the Neurological Sciences.

[33]  J. Morrison,et al.  Stereologic analysis of neurofibrillary tangle formation in prefrontal cortex area 9 in aging and Alzheimer’s disease , 2003, Neuroscience.

[34]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[35]  M. Goedert,et al.  Tau proteins with FTDP‐17 mutations have a reduced ability to promote microtubule assembly , 1998, FEBS letters.

[36]  R. Albin,et al.  Cholinergic vesicular transporters in progressive supranuclear palsy , 2002, Neurology.

[37]  John Q. Trojanowski,et al.  Abnormal tau phosphorylation at Ser396 in alzheimer's disease recapitulates development and contributes to reduced microtubule binding , 1993, Neuron.

[38]  Koji Abe,et al.  Accumulation of filamentous tau in the cerebral cortex of human tau R406W transgenic mice. , 2005, The American journal of pathology.

[39]  J. Hardy,et al.  The genetic and pathological classification of familial frontotemporal dementia. , 2001, Archives of neurology.

[40]  F. LaFerla,et al.  Lipopolysaccharide-Induced Inflammation Exacerbates Tau Pathology by a Cyclin-Dependent Kinase 5-Mediated Pathway in a Transgenic Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.

[41]  Hirotaka Yoshida,et al.  Abundant Tau Filaments and Nonapoptotic Neurodegeneration in Transgenic Mice Expressing Human P301S Tau Protein , 2002, The Journal of Neuroscience.

[42]  L Carlin,et al.  Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. , 1995, Archives of neurology.

[43]  B. Hyman,et al.  Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function , 2005, Science.

[44]  D L Price,et al.  A vector for expressing foreign genes in the brains and hearts of transgenic mice. , 1996, Genetic analysis : biomolecular engineering.

[45]  Akio Suzumura,et al.  Neuritic Beading Induced by Activated Microglia Is an Early Feature of Neuronal Dysfunction Toward Neuronal Death by Inhibition of Mitochondrial Respiration and Axonal Transport* , 2005, Journal of Biological Chemistry.

[46]  D. Selkoe.  Alzheimer's Disease Is a Synaptic Failure , 2002, Science.

[47]  M. J. Wade,et al.  Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. , 2001, Archives of neurology.

[48]  Nobuhisa Iwata,et al.  19F and 1H MRI detection of amyloid β plaques in vivo , 2005, Nature Neuroscience.

[49]  J. Trojanowski,et al.  Overexpression of the human NFM subunit in transgenic mice modifies the level of endogenous NFL and the phosphorylation state of NFH subunits , 1995, The Journal of cell biology.

[50]  Tetsuya Suhara,et al.  [(11)C]DAA1106: radiosynthesis and in vivo binding to peripheral benzodiazepine receptors in mouse brain. , 2003, Nuclear medicine and biology.

[51]  H. Akiyama,et al.  Cell mediators of inflammation in the Alzheimer disease brain. , 2000, Alzheimer disease and associated disorders.

[52]  S. Barger,et al.  Interleukin-1 Mediates Pathological Effects of Microglia on Tau Phosphorylation and on Synaptophysin Synthesis in Cortical Neurons through a p38-MAPK Pathway , 2003, The Journal of Neuroscience.

[53]  Chi Li,et al.  Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Bradley T. Hyman,et al.  Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease , 1992, Neurology.

[55]  C. Cotman,et al.  Transneuronal Degeneration in the Spread of Alzheimer's Disease Pathology: Immunohistochemical Evidence for the Transmission of Tau Hyperphosphorylation , 1997, Neurobiology of Disease.

[56]  K. Ashe,et al.  Age-Dependent Neurofibrillary Tangle Formation, Neuron Loss, and Memory Impairment in a Mouse Model of Human Tauopathy (P301L) , 2005, The Journal of Neuroscience.

[57]  M G Spillantini,et al.  Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. , 1999, Journal of neuropathology and experimental neurology.

[58]  J. Rabey,et al.  Phenotypic presentation of frontotemporal dementia with Parkinsonism‐chromosome 17 type P301S in a patient of Jewish‐Algerian origin , 2003, Movement disorders : official journal of the Movement Disorder Society.

[59]  John Q Trojanowski,et al.  Transgenic animal models of tauopathies. , 2005, Biochimica et biophysica acta.

[60]  A. Frankfurter,et al.  The distribution of tau in the mammalian central nervous system , 1985, The Journal of cell biology.

[61]  P. Cohen,et al.  Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. , 1994, The Biochemical journal.

[62]  J. Hodges,et al.  Tau Gene Mutation K257T Causes a Tauopathy Similar to Pick's Disease , 2000, Journal of neuropathology and experimental neurology.